Sponsor content
194 result(s) found, displaying 61 to 70
-
-
Prescription medicine decision summaryEbglyss (lebrikizumab) is for the treatment of moderate to severe atopic dermatitis (atopic eczema) in patients older than the age of twelve.
-
Prescription medicine registrationActive ingredients: lebrikizumab.
-
Australian Public Assessment Report (AusPAR)Omvoh (mirikizumab) has been approved for the treatment of moderately to severely active ulcerative colitis in adult patients
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 12.5 mg/0.5 mL solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 5 mg/0.5 mL solution for injection pre-filled pen.